Hua Yang

发表

Small molecule activation of PKM2 in cancer cells induces serine auxotrophy.

L. Cantley, C. Kung, J. Hixon, 2012, Chemistry & biology.

PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction

Hua Yang, C. Prakash, J. Bolleddula, 2021, CPT: pharmacometrics & systems pharmacology.

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

Hua Yang, K. Yen, O. Bernard, 2014 .

AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

Manish R. Patel, I. Flinn, R. Collins, 2014 .

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

Hua Yang, Fang Wang, Zenon Konteatis, 2017, Cancer discovery.

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

S. Gross, Giovanni Cianchetta, Cheng Fang, 2018, ACS medicinal chemistry letters.

Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects

Hua Yang, C. Prakash, S. Agresta, 2019, European Journal of Clinical Pharmacology.

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model

A. Kernytsky, Yaguang Si, S. Gross, 2016, Journal of Inherited Metabolic Disease.

Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation

Hua Yang, C. Dinardo, S. de Botton, 2020, Cancer Chemotherapy and Pharmacology.

ALDH2(E487K) mutation increases protein turnover and promotes murine hepatocarcinogenesis

T. Mak, C. Kung, J. Hixon, 2015, Proceedings of the National Academy of Sciences.

Evaluation of Pharmacokinetic-Pharmacodynamic (PKPD) Relationship of an Oral, Selective, First-in-Class, Potent IDH2 Inhibitor, AG-221, from a Phase 1 Trial in Patients with Advanced IDH2 Mutant Positive Hematologic Malignancies

Hua Yang, K. Yen, Fang Wang, 2014 .

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

P. Opolon, Hua Yang, K. Yen, 2014 .

Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML

R. Collins, S. Choe, Hua Yang, 2018, The New England journal of medicine.

Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies

Hua Yang, B. Poland, Xuemin Jiang, 2021, Clinical and translational science.

Physiologically based pharmacokinetic modeling and simulation to predict drug–drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia

Hua Yang, C. Prakash, K. Le, 2020, Cancer Chemotherapy and Pharmacology.

Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants

Hua Yang, Marvin B. Cohen, B. Fan, 2020, Clinical pharmacology in drug development.

AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency.

Yaguang Si, C. Kung, J. Hixon, 2017, Blood.

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

Fang Wang, Timothy A. Chan, Evangelia Komisopoulou, 2013, Science.

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

Fang Wang, Erica Hansen, Francesco G. Salituro, 2013, Science.

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.

Wei Liu, Fang Wang, Hua Yang, 2014, Blood.

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

I. Mellinghoff, Cheng Fang, Hua Yang, 2020, ACS medicinal chemistry letters.

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.

S. Gross, Shunqi Yan, J. Saunders, 2012, ACS medicinal chemistry letters.

Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma

Jeffrey W. Clark, A. Iafrate, D. Christiani, 2014, Clinical Cancer Research.

Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma

Jeffrey W. Clark, A. Iafrate, D. Christiani, 2014, Clinical Cancer Research.

A fit-for-purpose LC-MS/MS method for the simultaneous quantitation of ATP and 2,3-DPG in human K2EDTA whole blood.

C. Kung, Hua Yang, L. Dang, 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Phase 1 Single‐ and Multiple‐Ascending‐Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG‐348, a First‐in‐Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers

C. Kung, Hua Yang, M. Goldwasser, 2018, Clinical pharmacology in drug development.

Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study

D. Morton, C. Kung, J. Hixon, 2016 .

Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2‐Mutant Acute Myeloid Leukemia

Hua Yang, L. Hua, Yue Chen, 2022, Clinical pharmacology in drug development.

Abstract CT103: Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies

I. Flinn, Hua Yang, R. Levine, 2014 .

Ivosidenib (AG‐120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study: AML‐221

R. Collins, S. Choe, Hua Yang, 2018, Clinical Lymphoma Myeloma and Leukemia.

Quantitation of 2-hydroxyglutarate in human plasma via LC-MS/MS using a surrogate analyte approach.

Hua Yang, Fumin Li, Yonghua Ling, 2020, Bioanalysis.

Isocitrate dehydrogenase 1 and 2 mutations, 2‐hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia

A. Iafrate, D. Neuberg, Hua Yang, 2018, Cancer.

Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans

Hua Yang, S. Surapaneni, Yan Li, 2019, Xenobiotica; the fate of foreign compounds in biological systems.

Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies

Hua Yang, S. Agresta, K. Le, 2015 .

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Hua Yang, E. Attar, S. Agresta, 2015 .

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors

P. Wen, I. Mellinghoff, Hua Yang, 2019, Investigational New Drugs.

Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects

Hua Yang, C. Prakash, S. Agresta, 2019, Cancer Chemotherapy and Pharmacology.

DRIVE PK: A Phase 2 Trial of AG-348 in Patients with Pyruvate Kinase Deficiency

C. Kung, Hua Yang, B. Silver, 2015 .

1LBA Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies

Hua Yang, M. Tallman, R. Stone, 2014 .

Abstract B126: AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies

I. Mellinghoff, Hua Yang, K. Yen, 2018 .

Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies

Hua Yang, S. Su, L. Dang, 2021, Drug Metabolism and Disposition.

The Signature of Glycometabolism-Related Genes in Predicting the Prognosis of Patients with Osteosarcoma

Hua Yang, Yang Xiang, Hong Sun, 2022 .

Differentiation of Glioma Cells An Inhibitor of Mutant IDH 1 Delays Growth and Promotes

A. Kernytsky, C. Brennan, T. Graeber, 2013 .

AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model

S. Choe, Hua Yang, K. Yen, 2013 .

Abstract 2296: IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition

A. Kernytsky, W. Liu, Stuart Murray, 2014 .

An innovative phase I study in healthy subjects to determine the mass balance, elimination, metabolism, and absolute bioavailability of mitapivat

Hua Yang, C. Prakash, Yan Yan, 2023, Clinical and translational science.